The microenvironment and resistance to personalized cancer therapy

Nature Reviews Clinical Oncology

Volumn 10, Issue 2, 2013, Pages 79-

  Masuda, Shigeo ^a   Izpisua Belmonte, Juan Carlos ^a,b  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b CENTER OF REGENERATIVE MEDICINE IN BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CRIZOTINIB; GROWTH FACTOR; HEPATOCYTE GROWTH FACTOR NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUTRALIZING ANTIBODY; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; WNT16B PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; DISEASE ASSOCIATION; DNA DAMAGE; DRUG RESPONSE; HUMAN; LETTER; MELANOMA; MOLECULARLY TARGETED THERAPY; MUTANT; NONHUMAN; PATIENT DERIVED TUMOR XENOGRAFT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; STROMA CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; METHODOLOGY; NEOPLASM; NOTE; PHARMACOGENETICS;

HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACOGENETICS;

EID: 84873405923     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.127-c1     Document Type: Letter

References (5)

1. Meric-Bernstam, F. & Mills, G. B. Overcoming implementation challenges of personalized cancer therapy. Nat. Rev. Clin. Oncol. 9, 542-548 (2012).
2. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
3. Wilson, T. R. et al. Widespread potential for growthfactordriven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
4. Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18, 1359-1368 (2012).
5. Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338-350 (2012).